Doxepin Hydrochloride Capsule
FDA Label NDC 48433-038

Antidepressants increase the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)]. Doxepin hydrochloride capsules are not approved for use in pediatric patients [see Use in Specific Populations (8.4)].

Doxepin hydrochloride capsules are indicated for the treatment of major depressive disorder (MDD) in adults.

Prior to initiating treatment with doxepin hydrochloride capsules, screen patients for a personal or family history of bipolar disorder, mania, or hypomania [see Warnings and Precautions (5.5)].

The recommended starting oral dosage for doxepin hydrochloride capsules is 25 mg three times daily or 75 mg once daily. The recommended target total oral dosage range for doxepin hydrochloride capsules is between 75 mg/day and 150 mg/day (may be given once daily or in divided doses). The maximum recommended oral dosage for doxepin hydrochloride capsules is 100 mg three times daily.

Wait at least 14 days after discontinuation of a monoamine oxidase inhibitor (MAOI) before initiating therapy with doxepin hydrochloride capsules [see Contraindications (4), Warnings and Precautions (5.2), and Drug Interactions (7)] .

Wait at least 14 days after discontinuation of doxepin hydrochloride capsules before initiating therapy with an MAOI [see Contraindications (4), Warnings and Precautions (5.2), and Drug Interactions (7)].

If anticholinergic effects (e.g., dry mouth, blurred vision, constipation) develop, reduce the doxepin hydrochloride capsules dosage [seeAdverse Reactions (6.1)].

Reduce the doxepin hydrochloride capsules dosage based on doxepin plasma concentrations when used concomitantly with strong CYP2D6 inhibitors [seeDrug Interactions (7)].

Reduce the doxepin hydrochloride capsules dosage based on doxepin plasma concentrations in patients who are known CYP2D6 and CYP2C19 poor metabolizers [seeUse in Specific Populations (8.7)].

When discontinuing doxepin hydrochloride capsules, gradually reduce the dosage until discontinued [seeAdverse Reactions (6)] .

Doxepin Hydrochloride Capsules, USP are available containing doxepin hydrochloride, USP equivalent to 10 mg, 25 mg, 50 mg, 75 mg or 100 mg of doxepin.

• The 10 mg capsules are hard-shell, gelatin capsules with a buff opaque cap and buff opaque body axially printed with MYLANover 1049in black ink on both the cap and the body.
• The 25 mg capsules are hard-shell, gelatin capsules with an ivory opaque cap and white opaque body axially printed with MYLANover 3125in black ink on both the cap and the body.
• The 50 mg capsules are hard-shell, gelatin capsules with an ivory opaque cap and ivory opaque body axially printed with MYLANover 4250in black ink on both the cap and the body.
• The 75 mg capsules are hard-shell, gelatin capsules with a brite lite green opaque cap and brite lite green opaque body axially printed with MYLANover 5375in black ink on both the cap and the body.
• The 100 mg capsules are hard-shell, gelatin capsules with a brite lite green opaque cap and white opaque body axially printed with MYLANover 6410in black ink on both the cap and the body.

Doxepin hydrochloride capsules are contraindicated in patients:

• With hypersensitivity to doxepin (hypersensitivity reactions have included tongue edema and urticaria). The possibility of cross sensitivity with other dibenzoxepines should be kept in mind.
• With glaucoma [see Warnings and Precautions (5.3)].
• With current or past urinary retention [see Adverse Reactions (6.1)].
• Taking MAOIs, or within 14 days of stopping MAOIs (including the MAOIs linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2)and Drug Interactions (7)].

In pooled analyses of placebo-controlled trials of antidepressant drugs including tricyclic antidepressants and other antidepressant classes that included approximately 77,000 adult patients and 4,500 pediatric patients (doxepin hydrochloride capsules are not approved for use in pediatric patients), the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in Table 1.

It is unknown whether the risk of suicidal thoughts and behaviors in pediatric and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression.

Monitor all doxepin hydrochloride capsules-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of doxepin hydrochloride capsules therapy, and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the health care provider. Consider changing the therapeutic regimen, including possibly discontinuing doxepin hydrochloride capsules, in patients who are experiencing emergent suicidal thoughts or behaviors.

Tricyclic antidepressants, including doxepin hydrochloride capsules, can precipitate serotonin syndrome, a potentially life-threatening condition. This risk is increased with concomitant use of other serotonergic drugs (e.g., other tricyclic antidepressants, SSRIs, serotonin norepinephrine reuptake inhibitors, triptans, tetracyclic antidepressants, opioids), lithium, tryptophan, buspirone, and St. John’s Wort) and with drugs that impair metabolism of serotonin (e.g., MAOIs intended to treat psychiatric disorders and others, such as linezolid or intravenous methylene blue) [seeDrug Interactions (7)] .

Serotonin syndrome symptoms may include mental status changes (e.g., confusion, agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia, diaphoresis, and flushing), neuromuscular abnormalities (e.g., tremor, rigidity, clonus, and hyperreflexia), seizures and gastrointestinal signs and symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.

The concomitant use of doxepin hydrochloride capsules with MAOIs is contraindicated. The use of doxepin hydrochloride capsules within 14 days of discontinuing treatment with an MAOI intended to treat psychiatric disorders is contraindicated. Starting doxepin hydrochloride capsules in a patient who is being treated with an MAOI such as linezolid or intravenous methylene blue is contraindicated. No reports involved the administration of methylene blue by other routes (such as oral or local tissue injection). If it is necessary to initiate treatment with a MAOI such as linezolid or intravenous methylene blue in a patient taking doxepin hydrochloride capsules, discontinue doxepin hydrochloride capsules before initiating treatment with the MAOI [seeDosage and Administration (2.4)and Drug Interactions (7)] .

Monitor all patients taking doxepin hydrochloride capsules for the emergence of serotonin syndrome. Discontinue doxepin hydrochloride capsules treatment and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of doxepin hydrochloride capsules with other serotonergic drugs (besides MAOIs which are contraindicated) is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.

The pupillary dilation that occurs following use of many antidepressant drugs including doxepin hydrochloride capsules may trigger an angle closure glaucoma attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.

Doxepin hydrochloride capsules are contraindicated in patients with glaucoma. Avoid use of doxepin hydrochloride capsules in patients with untreated anatomically narrow angles.

Because doxepin hydrochloride capsules can cause sedation, warn patients of the risk of sedation and caution patients against driving a car or operating dangerous machinery while taking doxepin hydrochloride capsules. Also caution patients that their response to alcohol may be potentiated.

Sedating drugs, including doxepin hydrochloride capsules, may cause oversedation in geriatric patients.

In patients with bipolar disorder, treating MDD with doxepin hydrochloride capsules may precipitate a mixed/manic episode. Prior to initiating treatment with doxepin hydrochloride capsules, screen patients for any personal or family history of bipolar disorder, mania, or hypomania. doxepin hydrochloride capsules are not approved for use in treating bipolar depression.

Caution should be used when doxepin hydrochloride capsules are given to patients with a history of seizure disorder, because this drug may lower the seizure threshold. Patients with a history of seizures should be monitored during doxepin hydrochloride capsules use to identify recurrence of seizures or increase in frequency of seizures.

In patients with schizophrenia, treatment with doxepin hydrochloride capsules for MDD may activate psychosis. If this occurs, stop doxepin hydrochloride capsules and consider alternative treatment options.

The following clinically significant adverse reactions are described elsewhere in the labeling:

• Suicidal Thoughts and Behaviors in Adolescents and Young Adults [see Warnings and Precautions (5.1)]
• Serotonin Syndrome [see Warnings and Precautions (5.2)]
• Angle-Closure Glaucoma [see Warnings and Precautions (5.3)]
• Sedation and Driving Risks [see Warnings and Precautions (5.4)]
• Activation of Mania or Hypomania [see Warnings and Precautions (5.5)]
• Risk of Seizures [see Warnings and Precautions (5.6)]
• Psychosis [see Warnings and Precautions (5.7)]

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse reactions (≥ 2% of doxepin-treated patients) in 1,635 doxepin-treated patients with MDD in clinical trials included somnolence (17%), dry mouth (15%), dizziness (6%), constipation (5%), fatigue (5%), blurred vision (3%), tachycardia (3%), hypotension (3%), insomnia (2%), tremor (2%), nausea (2%), hyperhidrosis (2%), and increased weight (2%).

Other adverse reactions that occurred at an incidence of < 2% in patients treated with doxepin in clinical trials were:

• Ear and Labyrinth Disorders: Tinnitus.
• Gastrointestinal Disorders: Diarrhea, dyspepsia, vomiting.
• General Disorders and Administration Site Conditions: Asthenia, edema, chills.
• Metabolism and Nutrition Disorders: Decreased appetite.
• Nervous System Disorders: Ataxia, paresthesia, headache, extrapyramidal disorder.
• Psychiatric Disorders: Agitation, confusional state, libido decreased.
• Pulmonary Disorders: Asthma exacerbation.
• Renal and Urinary Disorders: Urinary retention.
• Reproductive System and Breast Disorders: Breast enlargement.
• Skin & Subcutaneous Tissue Disorders: Rash, pruritus.
• Vascular Disorders: Flushing.

The following adverse reactions have been identified during post-approval use of doxepin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

• Blood and Lymphatic System Disorders: Agranulocytosis, leukopenia, thrombocytopenia, eosinophilia, purpura.
• Cardiac Disorders: Conduction disorder, arrhythmia.
• Endocrine Disorders: Inappropriate antidiuretic hormone secretion.
• Eye Disorders: Angle-closure glaucoma, mydriasis.
• Gastrointestinal Disorders: Aphthous stomatitis, abdominal pain upper.
• General Disorders and Administration Site Conditions: Facial edema, hyperpyrexia.
• Hepatobiliary Disorders: Jaundice.
• Investigations: Blood glucose increased.
• Nervous System Disorders: Hypoesthesia, dysgeusia, convulsion, tardive dyskinesia, serotonin syndrome.
• Psychiatric Disorders: Hallucination, disorientation.
• Reproductive System and Breast Disorders: Testicular swelling, gynecomastia, galactorrhea.
• Skin and Subcutaneous Tissue Disorders: Photosensitivity reaction, tongue edema, alopecia, urticaria.
• Vascular Disorders: Hypertension.

Withdrawal syndrome occurred after stopping doxepin [see Drug Abuse and Dependence (9.3)].

The following adverse reaction has been reported with use with other tricyclic antidepressants: decreased blood glucose.

Table 2 describe the clinically significant drug interactions of doxepin hydrochloride capsules with other drugs or classes.

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including doxepin hydrochloride capsules, during pregnancy. Health care providers are encouraged to advise patients to register by calling the National Pregnancy Registry for Antidepressants 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/antidepressants.

Available data from published epidemiological studies and postmarketing reports have not established an increased risk for major birth defects or miscarriage with doxepin hydrochloride capsules use (see Data). There are risks (see Clinical Considerations) :

• To the mother associated with untreated depression in pregnancy.
• Poor neonate adaptation from exposure to tricyclic antidepressants (TCAs), including doxepin hydrochloride capsules, during the third trimester of pregnancy .

Animal reproduction toxicity of doxepin has not been fully characterized.

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data from published literature report the presence of doxepin and nordoxepin in human milk. There are reports of excessive sedation, respiratory depression, poor suckling and swallowing and hypotonia in breastfed infants exposed to doxepin at doses used to treat MDD. There are no data on the effects of doxepin on milk production.

Because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant, advise patients that breastfeeding is not recommended during doxepin hydrochloride capsules treatment.

Women who discontinue antidepressants during pregnancy are more likely to experience a relapse of MDD than women who continue antidepressants. This finding is from a prospective longitudinal study of 201 pregnant women with a history of MDD who were euthymic and taking antidepressants at the beginning of pregnancy. Consider the risk of untreated MDD when considering discontinuation of doxepin drugs during pregnancy and the postpartum period.

Neonates previously exposed to TCAs, including doxepin hydrochloride capsules, late in the third trimester during pregnancy have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These findings are consistent with either direct toxic effects of TCAs or possibly a drug discontinuation syndrome. Monitor neonates who were exposed to doxepin hydrochloride capsules in the third trimester of pregnancy for poor neonatal adaptation syndrome.

Published epidemiological studies of pregnant women exposed to TCAs, including doxepin hydrochloride capsules, have not established an association with major birth defects, miscarriage, or adverse maternal outcomes. Methodological limitations of these observational studies include small sample size and lack of adequate controls.

The safety and effectiveness of doxepin hydrochloride capsules in pediatric patients have not been established.

Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric patients [see Warnings and Precautions (5.1)] .

Clinical studies of doxepin did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

Sedating drugs, including doxepin hydrochloride capsules, may cause confusion and oversedation in geriatric patients. The recommended starting doxepin hydrochloride capsules dosage in geriatric patients is generally lower than those of younger adult patients .

The effect of hepatic impairment (HI) on the pharmacokinetics of doxepin has not been studied. Doxepin is primarily metabolized in the liver. Doxepin hydrochloride capsules-treated patients with HI may have a greater systemic doxepin exposure than those with normal liver function. Consider obtaining doxepin concentrations in patients with HI and modifying the dosage as appropriate.

The recommended doxepin hydrochloride capsules dosage in CYP2C19 and CYP2D6 poor metabolizers is lower than the recommended dosage in CYP2C19 and CYP2D6 normal metabolizers [see Dosage and Administration (2.6)].

According to the literature, doxepin is primarily metabolized by CYP2D6 and/or CYP2C19; thus, the use of doxepin hydrochloride capsules in CYP2D6 and/or CYP2C19 poor metabolizers will likely result in higher doxepin exposures and an increased risk of doxepin hydrochloride capsule-associated adverse reactions.

Doxepin hydrochloride capsules contain doxepin, which is not a controlled substance.

Doxepin hydrochloride capsules are not associated with abuse.

Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Abrupt cessation of doxepin hydrochloride capsules after prolonged administration can result in withdrawal symptoms, which is indicative of physical dependence.

Signs, Symptoms, and Complications of Doxepin Hydrochloride Capsules Overdose

Serious manifestations of tricyclic antidepressant (TCA) overdose include cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression, including coma. Deaths may occur from overdosage with TCAs, including doxepin hydrochloride capsules. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of TCA toxicity. A maximal limb-lead QRS duration of ≥ 0.1 seconds may be the best indication of the TCA overdose severity.

Signs and symptoms of TCA toxicity develop rapidly after TCA overdose. Other signs of TCA overdose may include confusion, disturbed concentration, transient visual hallucinations, dilated pupils, agitation, hyperactive reflexes, stupor, drowsiness, muscle rigidity, vomiting, hypothermia, or hyperpyrexia. There are reports of patients succumbing to fatal dysrhythmia late after TCA overdose.

Management of Overdose

The following are recommendations for the management of a doxepin hydrochloride capsules overdose. Contact the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

With a doxepin hydrochloride capsules overdose, obtain an ECG and immediately initiate cardiac monitoring in the hospital. A minimum of six hours of observation with cardiac monitoring and observation for signs of CNS depression, respiratory depression, hypotension, cardiac dysrhythmias, conduction blocks, and seizures is recommended. If signs of toxicity occur during this period, extended monitoring is recommended.

Monitoring of plasma doxepin levels should not guide doxepin hydrochloride capsules overdose management.

Cardiovascular Toxicity Management:Intravenous sodium bicarbonate should be administered to maintain the serum pH in the range of 7.45 to 7.55. If the pH response is inadequate to intravenous sodium bicarbonate therapy, hyperventilation may also be used. With concomitant use of hyperventilation and sodium bicarbonate therapy frequently monitor pH and pCO2. A pH > 7.6 or a pCO2 < 20 mm Hg is undesirable. Dysrhythmias unresponsive to intravenous sodium bicarbonate therapy/hyperventilation may respond to lidocaine therapy. Type 1A and 1C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide, and procainamide) in the setting of TCA overdose. Hemodialysis, peritoneal dialysis, exchange transfusions, and forced diuresis generally have been reported as ineffective in TCA overdose due to high tissue and protein binding of doxepin.

CNS Toxicity Management:In patients with TCA overdose who have CNS depression, early intubation is recommended because of the potential for abrupt deterioration. Seizures should be controlled with benzodiazepines, or if these are ineffective, other anticonvulsants (e.g., phenobarbital, propofol). Avoid use of physostigmine to treat TCA overdose.

Doxepin is a tricyclic antidepressant.

The molecular formula of doxepin hydrochloride is C ₁₉H ₂₁NO • HCl with a molecular weight of 315.84. It is a white crystalline powder freely soluble in water, in ethanol (96%), and methylene chloride. Doxepin is a dibenzoxepin derivative. Specifically, it is an isomeric mixture of: 1-Propanamine, 3-dibenz[ b, e]oxepin-11(6 H)ylidene- N, N-dimethyl-, hydrochloride. The structural formula of doxepin is shown below.

Doxepin Hydrochloride Structural Formula (Image 01)

Doxepin hydrochloride capsules are for oral administration.

Active ingredients for the capsules include: 10 mg, 25, mg, 50 mg, 75 mg and 100 mg of doxepin (equivalent to 11.4 mg, 28.5 mg, 57 mg, 85.5 mg and 114 mg of doxepin hydrochloride, respectively).

Capsule inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, pregelatinized starch (corn) and sodium lauryl sulfate. The empty gelatin capsule shells contain D&C Yellow No. 10, gelatin, sodium lauryl sulfate and titanium dioxide. In addition, the 10 mg, 25 mg and 50 mg empty gelatin capsule shells contain FD&C Yellow No. 6 and the 75 mg and 100 mg empty gelatin capsule shells contain FD&C Green No. 3.

The imprinting ink contains black iron oxide, D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, propylene glycol and shellac glaze.

The mechanism of action of the doxepin hydrochloride capsules in the treatment of MDD in adult patients is not well understood.

The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of doxepin have not been fully characterized.

In healthy volunteers, a single oral doxepin hydrochloride capsule dose of 75 mg resulted in peak plasma doxepin concentrations that ranged from 8.8 ng/mL to 45.8 ng/mL (mean 26.1 ng/mL). Peak levels were reached between 2 and 4 hours (mean 2.9 hours) after doxepin hydrochloride capsules administration. Peak levels for the primary active metabolite N-desmethyldoxepin (nordoxepin) ranged from 4.8 ng/mL to 14.5 ng/mL (mean 9.7 ng/mL) and were achieved between 2 and 10 hours after doxepin hydrochloride capsules administration.

The mean apparent volume of distribution for doxepin was approximately 20 L/kg. The protein binding for doxepin was approximately 76%.

In healthy volunteers, the plasma elimination half-life of doxepin ranged from 8 to 24 hours (mean 17 hours). The half-life of nordoxepin ranged from 33 to 80 hours (mean 51 hours). The mean plasma clearance for doxepin was approximately 0.84 L/hour/kg.

After oral doxepin administration, approximately 55% to 87% of doxepin undergoes first-pass metabolism in the liver, forming the primary active metabolite nordoxepin. Metabolic pathways of doxepin include demethylation, N-oxidation, hydroxylation and glucuronide formation.

Doxepin is excreted primarily in the urine, mainly as its metabolites, either free or in conjugate form.

Specific clinical studies have not been performed to evaluate the pharmacokinetics of doxepin in patients with hepatic impairment. Patients with hepatic impairment may have a greater systemic doxepin exposure than those with normal liver function [see Use in Specific Populations (8.6)].

The extent of renal excretion of doxepin is unknown. Specific clinical studies have not been performed to evaluate the pharmacokinetics of doxepin in patients with renal impairment compared to those with normal renal function.

After concomitant use of doxepin and carbamazepine, the combined exposure of doxepin and nordoxepin (12 hours after the last dose) was decreased by 55% compared to that after the use of doxepin alone [see Drug Interactions (7)].

CYP2D6 contributes to the metabolism of doxepin and concomitant use of doxepin with strong CYP2D6 inhibitors may increase doxepin exposure [see Drug Interactions (7)].

Cimetidine is a non-specific inhibitor of CYP1A2, 2C19, 2D6, and 3A4. When cimetidine 300 mg twice daily was administered concomitantly with a single 6 mg dose of another oral doxepin product, there was approximately a 2-fold increase in doxepin C _maxand AUC compared to doxepin without cimetidine [see Drug Interactions (7)] .

Concomitant use of doxepin and other CYP2D6 substrates may have impact on the plasma doxepin concentrations. The clinical significance of this possible impact is unknown.

The carcinogenic potential of doxepin in animals has not been fully characterized.

The mutagenetic potential of doxepin in animals has not been fully characterized.

Doxepin had no effect on female fertility in rats at oral doses up to 25 mg/kg/day (1.6x the human dose of 150 mg/day on a mg/m ²basis for a 60 kg human).

Insemination and conception were reduced in untreated female rats mated with male rats administered doxepin at 25 mg/kg/day for a period of ≥ 7 months.

How Supplied
Doxepin Hydrochloride Capsules, USP are available containing doxepin hydrochloride, USP equivalent to 10 mg, 25 mg, 50 mg, or 100 mg of doxepin.

The 10 mg capsules are hard-shell, gelatin capsules with a buff opaque cap and buff opaque body axially printed with MYLANover 1049in black ink on both the cap and the body. They are available as follows:

NDC 48433-035-20 – Unit dose blister packages of 100 (10 cards of 10 capsules each).

The 25 mg capsules are hard-shell, gelatin capsules with an ivory opaque cap and white opaque body axially printed with MYLANover 3125in black ink on both the cap and the body. They are available as follows:

NDC 48433-036-20 – Unit dose blister packages of 100 (10 cards of 10 capsules each).

The 50 mg capsules are hard-shell, gelatin capsules with an ivory opaque cap and ivory opaque body axially printed with MYLANover 4250in black ink on both the cap and the body. They are available as follows:

NDC 48433-037-20 – Unit dose blister packages of 100 (10 cards of 10 capsules each).

The 100 mg capsules are hard-shell, gelatin capsules with a brite lite green opaque cap and white opaque body axially printed with MYLANover 6410in black ink on both the cap and the body. They are available as follows:

NDC 48433-038-20 – Unit dose blister packages of 100 (10 cards of 10 capsules each).

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Protect from light.

PHARMACIST:Dispense a Medication Guide with each prescription.

Advise patients to read FDA-approved patient labeling (Medication Guide).

Suicidal Thoughts and Behaviors
Advise patients and caregivers to look for the emergence of suicidal thoughts and behaviors, especially early during doxepin hydrochloride capsules treatment and when the dosage is increased or decreased, and instruct them to report suicidal thinking and behavior to their health care provider [see Warnings and Precautions (5.1)].

Serotonin Syndrome
Caution patients about the risk of serotonin syndrome particularly with the concomitant use of doxepin hydrochloride capsules and other serotonergic drugs (e.g., other TCAs, SSRIs, SNRIs, triptans, opioids), lithium, tryptophan, buspirone, and St. John’s Wort and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid) [see Warnings and Precautions (5.2), Drug Interactions (7)]. Instruct patients to contact their health care provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome.

Angle-Closure Glaucoma
Advise patients that taking doxepin hydrochloride capsules can cause pupillary dilation, which in susceptible individuals, can trigger angle closure glaucoma. Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible [see Warnings and Precautions (5.3)] .

Effects on Driving and Operating Heavy Machinery
Inform patients that doxepin hydrochloride capsules can cause sedation and caution them against driving a car or operating dangerous machinery while taking doxepin hydrochloride capsules [see Warnings and Precautions (5.4)] .

Activation of Mania or Hypomania
Advise patients to observe for signs of mania/hypomania activation and instruct them to report such symptoms to the healthcare provider.

Drug Interactions
Inform patients that the use of doxepin hydrochloride capsules and certain other drugs increases the risk of doxepin hydrochloride capsule-associated adverse reactions or alternatively lower doxepin hydrochloride capsules effectiveness. Instruct patients to inform their healthcare provider about all the drugs that they are taking before taking doxepin hydrochloride capsules.

Alcohol Use
Advise patients to avoid the use of alcohol while taking doxepin hydrochloride capsules [see Drug Interactions (7)].

Pregnancy
Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to doxepin hydrochloride capsules during pregnancy. Advise women to notify their healthcare provider if they become pregnant or intend to become pregnant during doxepin hydrochloride capsules treatment.

Advise pregnant women that doxepin hydrochloride capsules use late in pregnancy may increase the risk for neonatal complications requiring prolonged hospitalization, respiratory support, or tube feeding [see Use in Specific Populations (8.1)].

Lactation
Advise patients that breastfeeding is not recommended during doxepin hydrochloride capsules treatment [see Use in Specific Populations (8.2)] .

This Medication Guide has been approved by the U.S. Food and Drug Administration .

Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.

Distributed by:
Safecor Health LLC
Rockford, IL 61103 U.S.A.

Revised: 10/2025
VPL:DXPN:RX

NDC 48433-035-20

Doxepin HCl
Capsules, USP
10 mg*

100 Capsules (10 x 10)

*Each capsule contains doxepin hydrochloride, USP
equivalent to 10 mg of doxepin.

Usual Daily Dosage:Mild to moderate symptomatology:
75 mg to 150 mg. Severe symptomatology: 150 mg to
300 mg. See package insert and Medication Guide for
complete dosage information.

Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room Temperature.]
Protect from light.

Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.

Rx only

S-13411

Distributed by:

Safecor Health LLC

Rockford, IL 61103 U.S.A.

This unit dose package is not child resistant.

For institutional use only.

Keep this and all drugs out of the reach of children.

This container provides light-resistance.

See window for lot number and expiration date.

Doxepin HCl Capsules, Usp 10 mg Unit Carton Label (Image 02)

Unit Carton (Image 03)

NDC 48433-036-20

Doxepin HCl
Capsules, USP
25 mg*

100 Capsules (10 x 10)

*Each capsule contains doxepin hydrochloride, USP
equivalent to 25 mg of doxepin.

Usual Daily Dosage:Mild to moderate symptomatology:
75 mg to 150 mg. Severe symptomatology: 150 mg to
300 mg. See package insert and Medication Guide for
complete dosage information.

Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room Temperature.]
Protect from light.

Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.

Rx only

S-13416

Distributed by:

Safecor Health LLC

Rockford, IL 61103 U.S.A.

This unit dose package is not child resistant.

For institutional use only.

Keep this and all drugs out of the reach of children.

This container provides light-resistance.

See window for lot number and expiration date.

Doxepin HCl 25 mg Capsules, Usp Unit Carton Label (Image 05)

Unit Carton (Image 07)

NDC 48433-037-20

Doxepin HCl
Capsules, USP
50 mg*

100 Capsules (10 x 10)

*Each capsule contains doxepin hydrochloride, USP
equivalent to 50 mg of doxepin.

Usual Daily Dosage:Mild to moderate symptomatology:
75 mg to 150 mg. Severe symptomatology: 150 mg to
300 mg. See package insert and Medication Guide for
complete dosage information.

Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room Temperature.]
Protect from light.

Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.

Rx only

S-13421

Distributed by:

Safecor Health LLC

Rockford, IL 61103 U.S.A.

This unit dose package is not child resistant.

For institutional use only.

Keep this and all drugs out of the reach of children.

This container provides light-resistance.

See window for lot number and expiration date.

Doxepin HCl Capsules, Usp 50 mg Unit Carton Label (Image 04)

Unit Carton (Image 06)

NDC 48433-038-20

Doxepin HCl
Capsules, USP
100 mg*

100 Capsules (10 x 10)

*Each capsule contains doxepin hydrochloride, USP
equivalent to 100 mg of doxepin.

Usual Daily Dosage:Mild to moderate symptomatology:
75 mg to 150 mg. Severe symptomatology: 150 mg to
300 mg. See package insert and Medication Guide for
complete dosage information.

Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room Temperature.]
Protect from light.

Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.

Rx only

S-13426

Distributed by:

Safecor Health LLC

Rockford, IL 61103 U.S.A.

This unit dose package is not child resistant.

For institutional use only.

Keep this and all drugs out of the reach of children.

This container provides light-resistance.

See window for lot number and expiration date.

Doxepin HCl Capsules, Usp 100 mg Unit Carton Label (Image 08)

Unit Carton (Image 09)